相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Juris J. Meier et al.
DIABETES CARE (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme
Denis Raccah et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2015)
Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials
Markolf Hanefeld et al.
ADVANCES IN THERAPY (2014)
C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study
Odd Erik Johansen et al.
DIABETES CARE (2014)
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Julio Rosenstock et al.
DIABETES CARE (2014)
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
John B. Buse et al.
DIABETES CARE (2014)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
C. Mathieu et al.
DIABETES OBESITY & METABOLISM (2014)
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2014)
Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains β-Cell Function in Patients With Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study
Yunjuan Zhao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials
Denis Raccah et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying - preclinical evidence
Ulrich Werner
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Bernard Charbonnel et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
Michael Horowitz et al.
ADVANCES IN THERAPY (2013)
Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype Action LADA 7
Mohammed I. Hawa et al.
DIABETES CARE (2013)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
C. Kapitza et al.
DIABETES OBESITY & METABOLISM (2013)
Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain
Angels Mollo et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway
Annalisa Natalicchio et al.
DIABETOLOGIA (2013)
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia
Martin Lorenz et al.
REGULATORY PEPTIDES (2013)
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Samuel S. Engel et al.
DIABETES THERAPY (2013)
Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data
Denis Raccah
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2013)
Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
Chun-jun Li et al.
CARDIOVASCULAR DIABETOLOGY (2012)
The Cardiovascular Effects of GLP-1 Receptor Agonists
Theodore Okerson et al.
CARDIOVASCULAR THERAPEUTICS (2012)
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Vanita R. Aroda et al.
CLINICAL THERAPEUTICS (2012)
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis
K. R. Gerrald et al.
DIABETES OBESITY & METABOLISM (2012)
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2012)
The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
D. Singh-Franco et al.
DIABETES OBESITY & METABOLISM (2012)
Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
S. -C. Liu et al.
DIABETES OBESITY & METABOLISM (2012)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Glucagon-Like Peptide-1 Counteracts Oxidative Stress-Dependent Apoptosis of Human Cardiac Progenitor Cells by Inhibiting the Activation of the c-Jun N-terminal Protein Kinase Signaling Pathway
L. Laviola et al.
ENDOCRINOLOGY (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
John B. Buse et al.
ANNALS OF INTERNAL MEDICINE (2011)
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
Jean Doucet et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up
Franco Cavalot et al.
DIABETES CARE (2011)
Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia
Itamar Raz et al.
DIABETES CARE (2011)
Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Matthew Riddle et al.
DIABETES CARE (2011)
LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
P. Barrington et al.
DIABETES OBESITY & METABOLISM (2011)
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
G. E. Umpierrez et al.
DIABETES OBESITY & METABOLISM (2011)
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
P. Barrington et al.
DIABETES OBESITY & METABOLISM (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes
Timothy Colin Hardman et al.
Diabetes Therapy (2011)
The Effect of Oral Antidiabetic Agents on A1C Levels
Diana Sherifali et al.
DIABETES CARE (2010)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Exendin-4 Prevents c-Jun N-Terminal Protein Kinase Activation by Tumor Necrosis Factor-alpha (TNF alpha) and Inhibits TNF alpha-Induced Apoptosis in Insulin-Secreting Cells
Annalisa Natalicchio et al.
ENDOCRINOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich Werner et al.
REGULATORY PEPTIDES (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Itamar Raz et al.
DIABETES CARE (2009)
β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults
Simona Cernea et al.
DIABETES CARE (2009)
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
M. A. Bush et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
Yan Gao et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions
Gregory M. Holmes et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Exendin-4 protects β-cells from interleukin-1β-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway
Mourad Ferdaoussi et al.
DIABETES (2008)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues
D. Tews et al.
HORMONE AND METABOLIC RESEARCH (2008)
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Jessica E. Matthews et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data
Rebecca J. Brown et al.
PEDIATRIC DIABETES (2008)
Insulin-associated weight gain in diabetes - causes, effects and coping strategies
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
When basal insulin therapy in type 2 diabetes mellitus is not enough - what next?
Denis Raccah et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Biologic actions and therapeutic potential of the proglucagon-derived peptides
DJ Drucker
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2005)
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c
L Monnier et al.
DIABETES CARE (2003)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
